EVMN.US Evommune, Inc.
- Market cap
- USD 277M
- P/E
- -
- P/B
- 1.05x
- ROE
- -38.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is EVMN.US undervalued?
Graham numberThe Graham number of Evommune, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Evommune, Inc. fundamental analysis
No fundamental analysis for Evommune, Inc. yet.
Evommune, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alt…
Full company profileEvommune, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Evommune, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 5.00M | 7.00M | 13.0M | 0.00 |
| Gross Profit | 4.00M | 5.71M | 13.0M | - |
| Operating Income | -37.9M | -70.0M | -81.1M | -118M |
| EBITDA | -33.0M | -65.5M | -79.7M | -116M |
| Net Income | -34.1M | -66.8M | -68.9M | -108M |
| EPS | -1.13 | -2.22 | -11 | -2.98 |
| Balance Sheet | ||||
| Total Assets | 82.2M | 76.1M | 225M | 302M |
| Total Liabilities | 160M | 220M | 19.4M | 24.4M |
| Shareholders' Equity | -77.7M | -144M | 206M | 278M |
| Cash & Short-term Investments | 79.1M | 72.0M | 149M | 201M |
| Total Debt | 151M | 193M | 1.71M | 8.11M |
| Cash Flow | ||||
| Operating Cash Flow | -30.0M | -58.2M | -76.4M | -95.6M |
| Capital Expenditure | 118K | 88.0K | 235K | 532K |
| Free Cash Flow | -30.1M | -58.3M | -76.7M | -96.2M |
| Ratios | ||||
| ROE | - | - | -33.5% | -38.8% |
| ROA | -41.4% | -87.8% | -30.6% | -35.7% |
| Net Profit Margin | -681.1% | -954.4% | -529.8% | - |
| Debt to Equity | - | - | 0.01x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Evommune, Inc. dividends
Evommune, Inc. has not paid dividends in the last 3 fiscal years.
Who owns Evommune, Inc.
- Insiders 3.15%
- Institutions 96.85%
- Public & others 0.00%
- Shares outstanding 36.3M
- Free float 22.7M
Top funds holding EVMN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Eventide Healthcare & Life Sciences I | 1.21M | 3.33% | 0.00% | Jun 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 739K | 2.04% | 0.00% | Sep 2026 |
| American Century Small Cap Growth Inv | 568K | 1.56% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 380K | 1.05% | 0.00% | Oct 2026 |
| T. Rowe Price New Horizons | 373K | 1.03% | -33.36% | Sep 2026 |
| Biotech Growth Ord | 161K | 0.44% | 0.00% | Jul 2026 |
| Fidelity Enhanced Small Cap Core ETF | 156K | 0.43% | +0.27% | Oct 2026 |
| Fidelity Small Cap Index | 149K | 0.41% | +7.30% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 146K | 0.40% | -0.38% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 114K | 0.31% | +0.23% | Oct 2026 |
| Fidelity Extended Market Index | 104K | 0.29% | +75.69% | Sep 2026 |
| Vanguard Russell 2000 ETF | 89.3K | 0.25% | +22.45% | Sep 2026 |
| CREF Total Global Stock Account R3 | 79.6K | 0.22% | 0.00% | Aug 2026 |
| VALIC Company I Small Cap Growth | 54.8K | 0.15% | 0.00% | Aug 2026 |
| Fidelity Total Market Index | 50.7K | 0.14% | +148.74% | Sep 2026 |
| iShares Micro-Cap ETF | 46.2K | 0.13% | 0.00% | Oct 2026 |
| ALPS Medical Breakthroughs ETF | 44.1K | 0.12% | 0.00% | Oct 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 39.6K | 0.11% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 39.4K | 0.11% | +131.65% | Sep 2026 |
| Schwab Small Cap Index | 37.5K | 0.10% | +21.55% | Sep 2026 |
Top institutions holding EVMN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| EQT Fund Management S.à r.l. | 5.29M | 14.57% | +7.28% | Jun 2026 |
| RA Capital Management, LLC | 3.49M | 9.63% | 0.00% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 1.94M | 5.35% | +73.45% | Jun 2026 |
| Pivotal bioVenture Partners Investment Advisor LLC | 1.93M | 5.31% | 0.00% | Jun 2026 |
| JPMorgan Chase & Co | 1.55M | 4.28% | +6.42% | Jun 2026 |
| RTW INVESTMENTS, LLC | 1.50M | 4.14% | 0.00% | Jun 2026 |
| Nan Fung Group Holdings Ltd | 1.44M | 3.97% | 0.00% | Jun 2026 |
| Point72 Asset Management, L.P. | 1.44M | 3.95% | +3,823.36% | Jun 2026 |
| Andera Partners | 1.39M | 3.84% | -26.64% | Jun 2026 |
| Eventide Asset Management, LLC | 1.21M | 3.33% | 0.00% | Jun 2026 |
| Vestal Point Capital LP | 1.00M | 2.76% | 0.00% | Jun 2026 |
| Jupiter Topco LLC | 897K | 2.47% | 0.00% | Jun 2026 |
| BlackRock Inc | 887K | 2.44% | +31.62% | Jun 2026 |
| Vanguard Capital Management, LLC | 882K | 2.43% | +93.80% | Jun 2026 |
| Baker Bros Advisors LP | 847K | 2.33% | 0.00% | Jun 2026 |
| Defilade Capital Management, L.P. | 793K | 2.19% | +16.88% | Jun 2026 |
| American Century Companies Inc | 755K | 2.08% | +53.17% | Jun 2026 |
| Alyeska Investment Group, L.P. | 704K | 1.94% | -3.02% | Jun 2026 |
| Balyasny Asset Management LLC | 457K | 1.26% | 0.00% | Jun 2026 |
| Velan Capital Investment Management LP | 451K | 1.24% | +1.12% | Jun 2026 |
Evommune, Inc. company profile
- Company name
- Evommune, Inc.
- Ticker
- EVMN.US
- Exchange
- USA Stocks
- Listed since
- Nov 6, 2025
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 48
- Fiscal year end
- December
- Address
- 1891 Page Mill Road, Palo Alto, CA, United States, 94304
- Phone
- (925) 247-4481
- Website
- evommune.com
About Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Evommune, Inc. management
9- Mr. Luis C. PenaFounder, President, CEO & Director · born 1963
- Mr. Kyle Carver CPA, M.B.A.Chief Financial Officer · born 1988
- Mr. Gregory S. Moss Esq.Chief Business & Legal Officer, Corporate Secretary and Chief Compliance Officer · born 1984
- Dr. Eugene Andrew Bauer M.D.Co-Founder, Chief Medical Officer & Director · born 1942
- Dr. Jeegar Patel Ph.D.Chief Scientific Officer · born 1978
- Ms. Janice Drew M.P.H.Chief of Development Operations · born 1963
- Dr. Lou Sehl Ph.D.Senior Vice President of Technical Operations
- Dr. Daniel J. Burge M.d.Senior Vice President of Clinical Development · born 1962
- Mr. J. Mark Jackson M.D.Senior Vice President of Clinical Development